Private company

Mirati Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2023 annual report the company says: “Mirati Therapeutics, Inc. is a commercial-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. We have multiple KRAS inhibitor programs.”70 It is headquartered in San Diego, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Incorporated inDE2
  • Business address3545 Cray Court, San Diego, Ca 921212
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-6108.0%Operating margin3
-5957.4%Net margin3
-82.7%Revenue growth, 20223
-74.3%Return on equity3
-$575.4MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development69¢$531.6M
  • Selling, general and admin31¢$239.8M
  • Income tax0¢$508.0K

Out of $12.4M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$12.4M in 2022
0$20.0M$40.0M$60.0M$80.0M2016: $0$020162017: $0$020172018: $12.9M$12.9M20182019: $3.3M$3.3M2019−74%2020: $13.4M$13.4M2020+302%2021: $72.1M$72.1M2021+438%2022: $12.4M$12.4M2022−83%
Operating income45673-$759.6M in 2022+807% since 2016
-$800.0M-$600.0M-$400.0M-$200.0M02016: -$83.8M-$83.8M20162017: -$71.5M-$71.5M2017−15%2018: -$102.6M-$102.6M2018+43%2019: -$222.1M-$222.1M2019+116%2020: -$369.4M-$369.4M2020+66%2021: -$573.2M-$573.2M2021+55%2022: -$759.6M-$759.6M2022+33%
Net income45673-$740.9M in 2022+791% since 2016
-$800.0M-$600.0M-$400.0M-$200.0M02016: -$83.1M-$83.1M20162017: -$70.4M-$70.4M2017−15%2018: -$98.4M-$98.4M2018+40%2019: -$213.3M-$213.3M2019+117%2020: -$357.9M-$357.9M2020+68%2021: -$581.8M-$581.8M2021+63%2022: -$740.9M-$740.9M2022+27%
Fiscal year2016201720182019202020212022
Revenue$04$05$12.9M6$3.3M7$13.4M3$72.1M3$12.4M3
Research and development$68.5M4$58.1M5$93.9M6$182.9M7$299.3M3$508.6M3$531.6M3
Selling, general and admin$83.4M3$136.7M3$239.8M3
Operating expenses$645.3M3$772.0M3
Operating income-$83.8M4-$71.5M5-$102.6M6-$222.1M7-$369.4M3-$573.2M3-$759.6M3
Income before tax-$578.5M3-$740.4M3
Income tax$04$05$06$07$03$3.3M3$508.0K3
Net income-$83.1M4-$70.4M5-$98.4M6-$213.3M7-$357.9M3-$581.8M3-$740.9M3
Earnings per share-$4.2011-$2.7811-$5.697-$7.963-$11.213-$13.183
Earnings per share (diluted)-$5.697-$7.963-$11.213-$13.183
Shares (weighted, basic)51.9M shares356.2M shares3
Shares (weighted, diluted)51.9M shares356.2M shares3

Compare Mirati Therapeutics, Inc. with another company

Corporate structure

Mirati Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Mirati Therapeutics, Inc.

  • ARMISTICE CAPITAL, LLC Filed SC 13G/A on Mirati Therapeutics, Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • Avoro Capital Advisors LLC Filed SC 13G/A on Mirati Therapeutics, Inc., latest Feb 14, 2024 (3 filings since Feb 11, 2022)
  • BAKER BROS. ADVISORS LP Filed SC 13G on Mirati Therapeutics, Inc., latest Feb 14, 2024
  • RTW INVESTMENTS, LP Filed SC 13G/A on Mirati Therapeutics, Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • VANGUARD GROUP INC Filed SC 13G/A on Mirati Therapeutics, Inc., latest Feb 13, 2024 (3 filings since Feb 10, 2022)
  • Morgan Stanley Filed SC 13G/A on Mirati Therapeutics, Inc., latest Feb 9, 2024 (2 filings since Feb 9, 2024)
  • Wellington Management Company Filed SC 13G/A on Mirati Therapeutics, Inc., latest Feb 8, 2024 (3 filings since Feb 4, 2022)
  • Boxer Capital, LLC Filed SC 13D/A on Mirati Therapeutics, Inc., latest Jan 25, 2024 (3 filings since Aug 16, 2023)
  • EcoR1 Capital, LLC Filed SC 13G/A on Mirati Therapeutics, Inc., latest Dec 27, 2023 (2 filings since Oct 2, 2023)
  • PERCEPTIVE ADVISORS LLC Filed SC 13G/A on Mirati Therapeutics, Inc., latest Feb 14, 2023 (2 filings since Feb 15, 2022)
  • FMR LLC Filed SC 13G/A on Mirati Therapeutics, Inc., latest Feb 9, 2022
  • Mirati Therapeutics, Inc. San Diego, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Mirati Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$23.0M3 Dec 31, 2022$18.6M3 Dec 31, 2021+23.5%
Accumulated depreciation$5.5M3 Dec 31, 2022$2.8M3 Dec 31, 2021+94.5%
Property and equipment, net$17.5M3 Dec 31, 2022$15.8M3 Dec 31, 2021+10.8%
Operating-lease assets (leased space)$36.1M3 Dec 31, 2022$37.7M3 Dec 31, 2021−4.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$235.3M3 Dec 31, 2022$413.1M3 Dec 31, 2021−43.0%
Marketable securities, current$848.6M3 Dec 31, 2022$1.1B3 Dec 31, 2021−21.3%
Debt securities available for sale$848.6M3 Dec 31, 2022$1.1B3 Dec 31, 2021−21.3%
Long-term investments$3.5M3 Dec 31, 2022$8.2M3 Dec 31, 2021−57.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$15.0M3 Dec 31, 2022$03 Dec 31, 2021
Accumulated amortization$86.0K3 Dec 31, 2022$03 Dec 31, 2021
Finite-lived intangibles, net$14.9M3 Dec 31, 2022$03 Dec 31, 2021

Inventory

ItemLatestA year beforeChange
Inventory, total$3.0M3 Dec 31, 2022$03 Dec 31, 2021
Raw materials$03 Dec 31, 2022$03 Dec 31, 2021
Work in process$3.0M3 Dec 31, 2022$03 Dec 31, 2021
Finished goods$26.0K3 Dec 31, 2022$03 Dec 31, 2021

Leadership

Who has led Mirati Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Charles M. Baum2013–2024

President

  1. Charles M. Baum2013–2024

Chief financial officer

  1. Jamie A. Donadio2016–2019
  2. Laurie Stelzer2022–2023
  3. Aaron Ondrey2023–2024

Chief operating officer

  1. Mark J. Gergen2013–2016
  2. Daniel Faga2020–2021
201520202025
Board members and other officers (24)

Timeline

  1. Jan 23, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer41
  2. Dec 19, 20238-K Other events42
  3. Dec 13, 20238-K Shareholder vote43
  4. Nov 24, 20238-K Other events44
  5. Nov 13, 20238-K Other events45
  6. Nov 6, 20238-K Results of operations46
  7. Oct 10, 20238-K Entered a material agreement; Bylaws or fiscal year changed; Other events47
  8. Aug 23, 20238-K Executive or director change; Regulation FD disclosure48
  9. Aug 9, 20238-K Other events49
  10. Aug 8, 20238-K Results of operations; Executive or director change; Regulation FD disclosure50
  11. Jul 21, 20238-K Other events51
  12. Jun 23, 20238-K Executive or director change52
  13. Jul 12, 2013New chief executive Charles M. Baum becomes CEO12

Calendar

When it reported results

  1. Nov 6, 2023Reported quarterly or annual results46
  2. Aug 8, 2023Reported quarterly or annual results50
  3. May 9, 2023Reported quarterly or annual results53
  4. Feb 28, 2023Reported quarterly or annual results54
  5. Jan 9, 2023Reported quarterly or annual results55
  6. Nov 8, 2022Reported quarterly or annual results56
  7. Aug 3, 2022Reported quarterly or annual results57
  8. May 4, 2022Reported quarterly or annual results58

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

217 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 36 major events, 109 insider forms, 24 large holders, 39 other. The latest 20:

  1. Feb 14, 2024SC 13G/A EDGAR
  2. Feb 14, 2024SC 13G EDGAR
  3. Feb 14, 2024SC 13G/A MIRATI THERAPEUTICS, INC. EDGAR
  4. Feb 14, 2024SC 13G/A MIRATI THERAPEUTICS, INC. EDGAR
  5. Feb 13, 2024SC 13G/A SCHEDULE 13G/A EDGAR
  6. Feb 9, 2024SC 13G/A MS AMENDMENT EDGAR
  7. Feb 9, 2024SC 13G MS INITIAL EDGAR
  8. Feb 8, 2024SC 13G/A SEC SCHEDULE 13G EDGAR
  9. Feb 2, 202415-12G EDGAR
  10. Jan 25, 20244 EDGAR
  11. Jan 25, 2024SC 13D/A EDGAR
  12. Jan 24, 2024EFFECT EDGAR
  13. Jan 24, 2024EFFECT EDGAR
  14. Jan 24, 2024EFFECT EDGAR
  15. Jan 23, 20244 EDGAR
  16. Jan 23, 20244 EDGAR
  17. Jan 23, 20244 EDGAR
  18. Jan 23, 20244 EDGAR
  19. Jan 23, 20244 EDGAR
  20. Jan 23, 20244 EDGAR

The 217 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

40 open-market trades by officers, directors and large owners since October 2021: 3 buys and 37 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 16, 2024Hickey BenjaminEVP, Chief Commercial OfficerSale1,597$59.02$94.3KForm 4
Jan 16, 2024Christensen JamieEVP & Chief Scientific OfficerSale1,597$59.02$94.3KForm 4
Jan 8, 2024Hickey BenjaminEVP, Chief Commercial OfficerSale2,090$58.92$123.1KForm 4
Jan 4, 2024Christensen JamieEVP & Chief Scientific OfficerSale1,531$58.81$90.0KForm 4
Dec 18, 2023Christensen JamieEVP & Chief Scientific OfficerSale2,387$57.50$137.3KForm 4
Dec 13, 2023Hickey BenjaminEVP, Chief Commercial OfficerSale2,220$56.67$125.8KForm 4
Sep 8, 2023Christensen JamieEVP & Chief Scientific OfficerSale2,388$35.63$85.1KForm 4
Aug 11, 2023Hasnain FaheemDirectorBuy10,791$27.80$300.0KForm 4
Aug 11, 2023Boxer Capital, LLCBuy1,258,973$27.80$35.0MForm 4
Aug 11, 2023MVA Investors, LLCBuy1,258,973$27.80$35.0MForm 4
Jun 2, 2023Stelzer LaurieChief Financial OfficerSale4,647$37.06$172.2KForm 4
May 24, 2023Christensen JamieEVP & Chief Scientific OfficerSale619$45.29$28.0KForm 4
Jan 18, 2023Cherrington Julie MDirectorSale2,546$44.66$113.7KForm 4
Jan 17, 2023Meek David D.Chief Executive OfficerSale3,179$42.38$134.7KForm 4
Jan 17, 2023Christensen JamieEVP & Chief Scientific OfficerSale2,245$42.38$95.1KForm 4
Jan 17, 2023Hickey BenjaminEVP, Chief Commercial OfficerSale1,566$42.38$66.4KForm 4
Jan 9, 2023Hickey BenjaminEVP, Chief Commercial OfficerSale2,088$45.37$94.7KForm 4
Jan 4, 2023BAUM CHARLES MFounder, President, and CEOSale3,648$46.60$170.0KForm 4
Jan 4, 2023Christensen JamieEVP & Chief Scientific OfficerSale1,949$46.60$90.8KForm 4
Dec 21, 2022BAUM CHARLES MFounder, President, and CEOSale9,092$40.42$367.5KForm 4

All 40 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Mirati Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMirati Therapeutics, Inc.1
  • CIK0001576263
  • Employer ID (EIN)46-26936151
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3545 Cray Court, San Diego, CA 921211
  • Phone858-332-34101
  • Shares outstanding70,147,706 as of Nov 1, 202310
  • Public float$3.7B as of Jun 30, 20223
  • On EDGAR sinceMay 10, 20131
  • Filings798 in all: 4 (360), 8-K (141), SC 13G/A (50), 3 (46), 10-Q (32), SC 13D/A (25), 424B5 (23), SC 13G (21)1
    All 40 form types

    S-8 (11), S-8 POS (11), 10-K (10), DEF 14A (10), DEFA14A (8), EFFECT (6), CT ORDER (5), 424B3 (4), CORRESP (3), POS AM (3), 10-12B/A (2), 4/A (2), ARS (2), S-3 (2), S-3ASR (2), SC 13D (2), UPLOAD (2), 10-12B (1), 10-Q/A (1), 15-12G (1), 25-NSE (1), 3/A (1), 424B4 (1), CERTNAS (1), DEFM14A (1), DFAN14A (1), POSASR (1), PREM14A (1), S-1 (1), S-1/A (1), S-1MEF (1), S-3MEF (1)

  • Latest filingsAnnual report (10-K) Feb 28, 2023
    Quarterly report (10-Q) Nov 6, 2023
    Proxy statement (DEF 14A) Apr 6, 2023
    Latest 8-K (8-K) Jan 23, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
    SEC EDGAROther events
  43. 43
  44. 44
    SEC EDGAROther events
  45. 45
    SEC EDGAROther events
  46. 46
  47. 47
  48. 48
  49. 49
    SEC EDGAROther events
  50. 50
  51. 51
    SEC EDGAROther events
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70